SetPoint MedicalAnnounced the completion of a $140 million private financing, including the second tranche of a $25 million Series C financing.Funding, as well as a $115 million Series D round led by Elevage Medical Technologies and Ally Bridge Group. In addition toElevage Medical Technologies and Ally Bridge Group, as well as Boston Scientific and Abbott,Existing shareholders such as Norwest, New Enterprise Associates (NEA), and Viking Global Investors continued to participate in the investment.The proceeds from this round of financing will be used to support the pioneering product.SetPointCommercialization,SetPointNeuroimmunomodulatory therapy for adult patients with moderate to severe rheumatoid arthritis, while advancing the company's R&D pipeline in other autoimmune disease areas."These strategic milestones mark our commitment to a seamless launch of SetPoint in selected U.S. markets this year, with plans to expand nationwide by 2026. We are honored to welcome outstanding new investors to join our distinguished consortium."---Murthy V. Simhambhatla SetPoint MedicalChief Executive OfficerSetPoint MedicalThe first product, a neuroimmunomodulatory stimulator---SetPointReceived FDA approval for marketing last month,Becoming the world's first approved neuroimmunomodulatory stimulator. Providing a new treatment option for rheumatoid arthritis patients, especially thosePharmacotherapy offers new hope for many patients with poor efficacy or drug intolerance.The launch of such a revolutionary product implies the need to rapidly advance commercialization. To this endSetPoint MedicalThe introduction of two heavyweight marketing professionalsAddressing issues in the commercialization process. The first is the appointment of a Vice President of Sales.Erik Styacich(Former Vice President of Sales at Valencia Technologies, a neuromodulation company), the second is Spencer Bailey, who serves as the Vice President of Market Access and Medical Insurance Reimbursement (having held similar leadership positions in several neuromodulation companies, such asMicroTransponder）。In the case of having money, people, and unique global technology,SetPointWill become a shining pearl in the market, with the expectation that innovative technology will benefit tens of millions of rheumatoid arthritis patients.
SetPoint
SetPointIt is a small neurostimulator that is placed around the left vagus nerve through a narrow incision in the neck during a brief outpatient surgery. Its working principle isOnce-daily vagus nerve stimulationTo activate innate anti-inflammatory and immune repair pathways, thereby reducing inflammation levels。
SetPointConsists of an implantable microstimulator, a wireless charger, and an iPad APP.
SetPointImplantable MicrostimulatorUtilizes integrated circuits, telemetry hardware, and a rechargeable battery encapsulated in a ceramic and titanium alloy casing to generate precise electrical pulses. It is extremely compact in size., volume less than< 2ml。Through a tinyCan be implanted into the neck through an incisionAround the left vagus nerve.SetPointThe implantable microstimulator can connect via Bluetooth withiPad Connected to the APP,Doctor ThroughiPad APPDetermine Precise ControlSetPointThePulse Dose Auto-Release。SetPointThe implantable microstimulator can be used for at least ten years after a single implantation. To ensure the stimulator always has sufficient power, it can be achieved throughThe wireless charger regularly charges the stimulator, and the charging process is simple and convenient.SetPoint Medical Treatment Mechanism:The vagus nerve is the longest nerve in the body.Innervate many organs. ItsComposed of thousands of sensory and motor neurons. Sensory neurons detect and respond to inflammatory mediators by sending signals to the brainstem, where reflexive signals are generated. This new signal is transmitted by motor neurons within the vagus nerve to the splenic nerve, leading to the release of norepinephrine in the spleen. Special CD4+ T lymphocytes (T cells) expressing adrenergic receptors in the spleen take up norepinephrine and release acetylcholine, which then binds to α7 nicotinic receptors on immune cells. This process reduces intracellular inflammation. Thus, the vagus nerve plays a central role in decreasing the production of inflammatory cytokines.SetPointIn addition to treating rheumatoid arthritis, it can also treat inflammatory bowel disease (IBD), psoriasis, multiple sclerosis, and more.
SetPoint MedicalSetPoint Medical is an innovative medical device company dedicated to treating patients with chronic autoimmune diseases. It is developing a novel platform designed to stimulate vagus nerve activation of neuroimmune pathways, thereby producing systemic anti-inflammatory and immune-restorative effects.
